AR053359A1 - Sintesis y preparaciones de polimorfos de aripiprazol cristalino - Google Patents

Sintesis y preparaciones de polimorfos de aripiprazol cristalino

Info

Publication number
AR053359A1
AR053359A1 ARP060101486A ARP060101486A AR053359A1 AR 053359 A1 AR053359 A1 AR 053359A1 AR P060101486 A ARP060101486 A AR P060101486A AR P060101486 A ARP060101486 A AR P060101486A AR 053359 A1 AR053359 A1 AR 053359A1
Authority
AR
Argentina
Prior art keywords
synthesis
polymorphes
aripiprazol
preparations
crystal
Prior art date
Application number
ARP060101486A
Other languages
English (en)
Inventor
Velez Monica Benito
I Grau Elies Molins
Aguilar Carmen Arnalot
Bernardino Mangion
Original Assignee
Medichem Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medichem Sa filed Critical Medichem Sa
Publication of AR053359A1 publication Critical patent/AR053359A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Formas polimorfas cristalinas de aripiprazol, procesos de síntesis para su preparacion y composiciones farmacéuticas que las contienen. Estas formas cristalinas de aripiprazol pueden molerse fácilmente y se pueden combinar fácilmente con diferentes coadyuvantes farmacéuticos sin realizar cambios en su estructura cristalina, por ejemplo, cuando se comprimen para darles forma de cápsula o tableta
ARP060101486A 2005-04-15 2006-04-17 Sintesis y preparaciones de polimorfos de aripiprazol cristalino AR053359A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67152405P 2005-04-15 2005-04-15
US73612805P 2005-11-14 2005-11-14

Publications (1)

Publication Number Publication Date
AR053359A1 true AR053359A1 (es) 2007-05-02

Family

ID=37084716

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060101486A AR053359A1 (es) 2005-04-15 2006-04-17 Sintesis y preparaciones de polimorfos de aripiprazol cristalino

Country Status (6)

Country Link
US (1) US20090247542A1 (es)
EP (1) EP1879865A1 (es)
AR (1) AR053359A1 (es)
CA (1) CA2605128A1 (es)
IL (1) IL186617A0 (es)
WO (1) WO2007004061A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7714129B2 (en) 2003-12-16 2010-05-11 Teva Pharmaceutical Industries Ltd. Methods of preparing anhydrous aripiprazole form II
CN101351192A (zh) 2006-01-05 2009-01-21 特瓦制药工业有限公司 阿立哌唑的湿法制粒的药用组合物
GB0618879D0 (en) 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions
WO2008051541A2 (en) 2006-10-24 2008-05-02 Cambrex Charles City, Inc. Process for preparing anhydrous aripirazole type i
EP2238976B1 (en) 2009-04-03 2012-06-27 Hexal AG Oral films comprising 7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro- 1H-quinolin-2-one base or salts or hydrates thereof
CN102106826B (zh) * 2009-12-29 2013-06-05 上海中西制药有限公司 一种阿立哌唑固体制剂及其制备方法
US20180155290A1 (en) * 2015-05-08 2018-06-07 Davuluri Ramamohan Rao Improved Process for the Preparation of Aripiprazole with Reduced Particle Size
CN114177868A (zh) * 2021-12-14 2022-03-15 辰欣药业股份有限公司 一种阿立哌唑的制备方法及装置

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR033485A1 (es) * 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
EP1606262A1 (en) * 2003-03-21 2005-12-21 Hetero Drugs Limited Novel crystalline forms of aripiprazole
US20060270683A1 (en) * 2003-04-25 2006-11-30 Lohray Braj B Polymorphs of aripiprazole
WO2005009990A1 (en) * 2003-07-25 2005-02-03 Hetero Drugs Limited Aripiprazole crystalline forms
WO2005058835A2 (en) * 2003-12-16 2005-06-30 Teva Pharmaceutical Industries Ltd. Methods of preparing aripiprazole crystalline forms
WO2006012237A2 (en) * 2004-06-25 2006-02-02 Shanghai Institute Of Pharmaceutical Industry Aripiprazole crystaline forms and associated methods
WO2006053780A1 (en) * 2004-11-18 2006-05-26 Synthon B.V. Crystalline aripiprazole solvates
EP1686117A1 (en) * 2005-01-27 2006-08-02 Sandoz AG Polymorph and solvates of aripiprazole

Also Published As

Publication number Publication date
WO2007004061A1 (en) 2007-01-11
EP1879865A1 (en) 2008-01-23
CA2605128A1 (en) 2007-01-11
US20090247542A1 (en) 2009-10-01
IL186617A0 (en) 2008-01-20

Similar Documents

Publication Publication Date Title
AR053359A1 (es) Sintesis y preparaciones de polimorfos de aripiprazol cristalino
ECSP088859A (es) Nueva forma cristalina vi de la agomelatina, su procedimiento de preparación y las composiciones farmacéuticas que la contienen
CU20060038A7 (es) Forma cristalina gamma-d del clorhidrato de la ivabradina, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
ECSP066914A (es) FORMA CRISTALINA dd DEL CLORHIDRATO DE LA IVABRADINA, SU PROCEDIMIENTO DE PREPARACIÓN Y LAS COMPOSICIONES FARMACÉUTICAS QUE LA CONTIENEN
CU23614B7 (es) Forma cristalina beta del clorhidrato de la ivabradina, su procedimiento de preparación y las composiciones farmacéuticas que la contienen
CU20060037A7 (es) Forma cristalina gamma del clorhidrato de la ivabradina, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
BRPI0809667A2 (pt) Composto, medicamento e composição farmacêutica que o contém e uso do composto
ECSP088750A (es) Métodos y composiciones para antagonismo de rage
DK1695710T3 (da) Krystallinsk betad-form af ivabradinhydrochlorid, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende denne
CL2008001839A1 (es) Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades.
CL2006001266A1 (es) Formas solidas cristalinas i, ii, iii, iv y v de tigeciclina; procedimiento de preparacion de las formas cristalinas ii, iv y v; composicion farmaceutica que comprende las formas cristalinas; y su uso para tratar infecciones bacterianas.
TW200732323A (en) Organic compounds
HN2006014095A (es) Forma cristalina ortorrombica del maleato de asenapina
EA200702589A1 (ru) 2,6-хинолинильные производные, способы их получения и их применение
JO2770B1 (en) Organic compounds
ATE485261T1 (de) Salicylsäurederivate
CR10229A (es) Derivados de 1,2,4,5,-tetrahidro-3h-benzazepinas, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
DK1642897T3 (da) Alfa-krystalform af strontiumranelat, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse
ITMI20061672A1 (it) Formulazioni di acido acetilsalicilico o suoi derivati in capsule molli,esibenti elevata stabilita'
WO2006136580A3 (en) 2-(phenylamino)benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels
BR112012032248A2 (pt) composições de 5-etil-2-{4-[-4(-4-tetrazol-1-il-fenoximetil)-tiazol-2-il]-piperidin-1-il}-pirimidina
DK1869038T3 (da) Substituerede 5,6,7,8-tetrahydro-imidazol[1,2-a]pyridin-2-ylamin-forbindelser og deres anvendelse til fremstilling af lægemidler
CY1112973T1 (el) Περαιτερω κρυσταλλικες μορφες ροσταφουροξινης
ECSP088464A (es) Compuesto para la inhibición de la apoptosis
GB0615105D0 (en) Novel compounds

Legal Events

Date Code Title Description
FB Suspension of granting procedure